A first-of-its-kind human clinical study in Alzheimer’s disease patients has found that a supplement ‘cocktail’ significantly improved cognitive function and associated biomarkers of the disease. ChromaDex Corp, a global bioscience company, last week announced the promising findings from its clinical study. The study was a randomised, double-blinded, placebo-controlled human phase II study of 60...
More strategies for the brain are needed and quickly